Nabiqasim Industries (Pvt) Ltd.,
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan-based pharmaceutical manufacturer producing branded generic formulations with domestic and international operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Nabiqasim Industries (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi, Pakistan
- Website
- nabiqasim.com ↗
- Phone
- +92 21 111 742 762
- info@nabiqasim.com
- Official contact
- Contact page ↗
- Official company profile ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Clarithro | Clarithromycin | 250 mg | Tablet | 10's | 025908 | PKR 571.18 | PKR 57.12/tablet | 20% above median |
| Clarithro | Clarithromycin | 500 mg | Tablet | 10's | 025909 | PKR 1,107.22 | PKR 110.72/tablet | 33% above median |
| Clarithro | Clarithromycin | 125 mg/5 mL | Suspension | 60ml | 025910 | PKR 458.05 | PKR 7.63/mL | Near median |
| Clarithro | Clarithromycin | 125 mg/5 mL | Suspension | 30ml | 025910 | PKR 214.79 | PKR 7.16/mL | Near median |
| Clarithro | Clarithromycin | 500 mg | Prolonged-release tablet | 5's | 055654 | PKR 460.57 | PKR 92.11/tablet | Near median |
| Clarithro | Clarithromycin | 500 mg | Prolonged-release tablet | 10's | 055654 | PKR 919.08 | PKR 91.91/tablet | Near median |
| Clarithro | Clarithromycin | 500 mg | IV injection | 1's | 070891 | PKR 456.82 | PKR 456.82/vial/unit | No comparator |
| Clarithro | Clarithromycin | 250 mg/5 mL | Dry suspension | 70ml | 073693 | PKR 888.10 | PKR 12.69/mL | 12% above median |
| Clomitab | Clomifene citrate | 50 mg | Tablet | 30's | 011793 | PKR 1,422.07 | PKR 47.40/tablet | 14% above median |
| Cloxipa | Apixaban | 2.5 mg | Tablet | 30's | 110444 | PKR 3,418.99 | PKR 113.97/tablet | Near median |
| Cloxipa | Apixaban | 5 mg | Tablet | 30's | 110445 | PKR 3,634.59 | PKR 121.15/tablet | Near median |
| Co-Depricap | Olanzapine + Fluoxetine | 6 mg + 25 mg | Capsule | 14's | 076135 | PKR 506.46 | PKR 36.18/capsule | 20% above median |
| Co-Depricap | Olanzapine + Fluoxetine | 6 mg + 25 mg | Capsule | 10's | 076135 | PKR 362.43 | PKR 36.24/capsule | 20% above median |
| Co-Depricap | Olanzapine + Fluoxetine | 3 mg + 25 mg | Capsule | 20's | 076136 | PKR 411.21 | PKR 20.56/capsule | 18% above median |
| Co-Depricap | Olanzapine + Fluoxetine | 3 mg + 25 mg | Capsule | 10's | 076136 | PKR 216.06 | PKR 21.61/capsule | 24% above median |
| Co-Depricap | Olanzapine + Fluoxetine | 3 mg + 25 mg | Capsule | 14's | 076136 | PKR 302.01 | PKR 21.57/capsule | 24% above median |
| Co-Depricap | Olanzapine + Fluoxetine | 12 mg + 25 mg | Capsule | 10's | 097334 | PKR 521.77 | PKR 52.18/capsule | Near median |
| Co-Depricap | Olanzapine + Fluoxetine | 12 mg + 25 mg | Capsule | 14's | 097334 | PKR 730.47 | PKR 52.18/capsule | Near median |
| Cortec | Enalapril | 5 mg | Tablet | 20's | 014881 | PKR 132.67 | PKR 6.63/tablet | 33% above median |
| Cortec | Enalapril | 10 mg | Tablet | 20's | 014882 | PKR 339.36 | PKR 16.97/tablet | 135% above median |
| Cortec Plus | Enalapril + Hydrochlorothiazide | 10 mg + 25 mg | Tablet | 20's | 039475 | PKR 219.78 | PKR 10.99/tablet | 20% below median |
| Dapxi | Dapagliflozin | 10 mg | Tablet | 14's | 110209 | PKR 883.89 | PKR 63.14/tablet | 8% below median |
| Dapxi | Dapagliflozin | 10 mg | Tablet | 10s | 110209 | PKR 662.54 | PKR 66.25/tablet | Near median |
| Dapxi | Dapagliflozin | 5 mg | Tablet | 14's | 110382 | PKR 836.77 | PKR 59.77/tablet | 8% below median |
| Dapxi | Dapagliflozin | 5 mg | Tablet | 10s | 110382 | PKR 597.70 | PKR 59.77/tablet | 8% below median |
| Dapxi Met | Dapagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 56s | 110208 | PKR 3,194.46 | PKR 57.04/tablet | Near median |
| Dapxi Met | Dapagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 28s | 110208 | PKR 1,630.21 | PKR 58.22/tablet | Near median |
| Dapxi Met | Dapagliflozin + Metformin | 5 mg + 850 mg | Tablet | 56s | 110381 | PKR 3,189.07 | PKR 56.95/tablet | Near median |
| Dapxi Met | Dapagliflozin + Metformin | 5 mg + 850 mg | Tablet | 28s | 110381 | PKR 1,627.52 | PKR 58.13/tablet | Near median |
| Dapxi Met + | Dapagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 14s | 110208 | PKR 831.93 | PKR 59.42/tablet | Near median |
| Dapxi Met + | Dapagliflozin + Metformin | 5 mg + 850 mg | Tablet | 14s | 110381 | PKR 830.59 | PKR 59.33/tablet | Near median |
| Dapxi-Met XR | Dapagliflozin + Metformin | 5 mg + 500 mg | Tablet | 14's | 120012 | PKR 1,021.74 | PKR 72.98/tablet | No comparator |
| Dapxi-Met XR | Dapagliflozin | 5 mg | Tablet | 28's | 120012 | PKR 2,003.10 | PKR 71.54/tablet | 10% above median |
| Deplat | Clopidogrel | 75 mg | Tablet | 10's | 033381 | PKR 221.95 | PKR 22.20/tablet | 18% below median |
| Deplat-AP | Clopidogrel + Aspirin | 75 mg + 75 mg | Tablet | 10's | 053139 | PKR 271.81 | PKR 27.18/tablet | Near median |
| Deplat-AP | Clopidogrel + Aspirin | 75 mg + 150 mg | Tablet | 10's | 061449 | PKR 291.22 | PKR 29.12/tablet | Near median |
| Depricap | Fluoxetine | 20 mg | Capsule | 30's | 013543 | PKR 1,517.71 | PKR 50.59/capsule | 290% above median |
| Dermosporin | Clotrimazole | 1 % | Solution | 60ml (additional Pack) | 009838 | PKR 162.46 | PKR 2.71/mL | No comparator |
| Dermosporin-B | Betamethasone + Clotrimazole | 10 mg/g + 0.5 mg/g | Cream | 10gm | 067443 | PKR 86.49 | PKR 8.65/g | No comparator |
| Dermosporin-HC | Clotrimazole + Hydrocortisone | 1% + 1% | Cream | 10gm | 067526 | PKR 127.07 | PKR 12.71/g | Near median |
| Dervit | Calcipotriol | 50 mcg/g | Ointment | 30g | 067444 | PKR 1,556.01 | PKR 51.87/g | Near median |
| Dervit B | Calcipotriol + Betamethasone | 50 mcg/g + 0.5 mg/g | Ointment | 30gm | 067445 | PKR 1,674.00 | PKR 55.80/g | 14% above median |
| Dervit B | Calcipotriol + Betamethasone | 50 mcg/g + 0.5 mg/g | Ointment | 15gm | 067445 | PKR 734.21 | PKR 48.95/g | 12% below median |
| Descol | Atorvastatin | 10 mg | Tablet | 10's | 031841 | PKR 384.43 | PKR 38.44/tablet | 39% above median |
| Descol | Atorvastatin | 20 mg | Tablet | 10's | 031842 | PKR 748.62 | PKR 74.86/tablet | 60% above median |
| Descol | Atorvastatin | 40 mg | Tablet | 10's | 031843 | PKR 1,497.24 | PKR 149.72/tablet | 99% above median |
| DIAMET | Metformin | 250 mg | Tablet | 50's | 055585 | PKR 116.99 | PKR 2.34/tablet | Near median |
| Diamet | Metformin | 250 mg | Tablet | 30's | 055585 | PKR 70.19 | PKR 2.34/tablet | Near median |
| DIAMET | Metformin | 500 mg | Tablet | 50's | 055586 | PKR 164.15 | PKR 3.28/tablet | 22% above median |
| Diasol | Oral rehydration salts (ORS) | NaCl 3.5 g + KCl 1.5 g + NaHCO3 2.5 g + glucose 20 g/sachet | Sachet | 1's | 008506 | PKR 17.26 | PKR 17.26/sachet | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.